| Primary |
| Filariasis Lymphatic |
44.4% |
| Helminthic Infection |
22.2% |
| Drug Use For Unknown Indication |
12.0% |
| Onchocerciasis |
6.0% |
| Ascariasis |
3.2% |
| Infection Parasitic |
1.9% |
| Echinococciasis |
1.4% |
| Dyspnoea |
0.9% |
| Endometritis |
0.9% |
| Hypertension |
0.9% |
| Neurocysticercosis |
0.9% |
| Strongyloidiasis |
0.9% |
| Visceral Larva Migrans |
0.9% |
| Abdominal Pain |
0.5% |
| Asthma |
0.5% |
| Cholestasis |
0.5% |
| Cutaneous Larva Migrans |
0.5% |
| Dehydration |
0.5% |
| Epilepsy |
0.5% |
| Gastritis |
0.5% |
|
| Vomiting |
38.6% |
| Drug Exposure During Pregnancy |
8.3% |
| Vision Blurred |
6.8% |
| Death |
4.5% |
| Stevens-johnson Syndrome |
4.5% |
| Pyrexia |
3.8% |
| Toxic Epidermal Necrolysis |
3.8% |
| Transaminases Increased |
3.8% |
| Abortion Spontaneous |
3.0% |
| Convulsion |
3.0% |
| Loss Of Consciousness |
3.0% |
| Asphyxia |
2.3% |
| Cardiac Arrest |
2.3% |
| Headache |
2.3% |
| Syncope |
2.3% |
| Cognitive Disorder |
1.5% |
| Completed Suicide |
1.5% |
| Death Neonatal |
1.5% |
| Hepatic Function Abnormal |
1.5% |
| Injury Asphyxiation |
1.5% |
|
| Secondary |
| Filariasis Lymphatic |
30.6% |
| Onchocerciasis |
24.0% |
| Product Used For Unknown Indication |
7.3% |
| Hiv Infection |
6.9% |
| Strongyloidiasis |
4.5% |
| Angioimmunoblastic T-cell Lymphoma |
3.1% |
| Helminthic Infection |
3.1% |
| Enterobacter Bacteraemia |
2.8% |
| Proteus Infection |
2.8% |
| Streptococcal Bacteraemia |
2.8% |
| Pneumonia Fungal |
2.4% |
| Filariasis |
2.1% |
| Drug Abuse |
1.7% |
| Parasitic Infection Intestinal |
1.0% |
| Self Injurious Behaviour |
1.0% |
| Sjogren's Syndrome |
1.0% |
| Antibiotic Therapy |
0.7% |
| Echinococciasis |
0.7% |
| Epilepsy |
0.7% |
| Prophylaxis |
0.7% |
|
| Pyrexia |
14.9% |
| Toxic Epidermal Necrolysis |
13.5% |
| Stevens-johnson Syndrome |
9.5% |
| Strongyloidiasis |
6.8% |
| Dysarthria |
5.4% |
| Drug Exposure During Pregnancy |
4.1% |
| Renal Failure Acute |
4.1% |
| Skin Exfoliation |
4.1% |
| Ulcer |
4.1% |
| Vertigo |
4.1% |
| Vomiting |
4.1% |
| Weight Decreased |
4.1% |
| Asthenia |
2.7% |
| Drug Ineffective |
2.7% |
| Encephalopathy |
2.7% |
| Incoherent |
2.7% |
| Klebsiella Bacteraemia |
2.7% |
| Nervous System Disorder |
2.7% |
| Syncope |
2.7% |
| Urinary Incontinence |
2.7% |
|
| Concomitant |
| Product Used For Unknown Indication |
26.6% |
| Visceral Leishmaniasis |
10.8% |
| Hiv Infection |
8.8% |
| Sleep Disorder Therapy |
7.0% |
| Hypertension |
4.3% |
| Prophylaxis |
4.3% |
| Hodgkin's Disease Recurrent |
3.5% |
| Infection Parasitic |
3.5% |
| Tremor |
3.1% |
| Hodgkin's Disease |
2.9% |
| Analgesic Therapy |
2.7% |
| Hyperuricaemia |
2.7% |
| Isosporiasis |
2.7% |
| Relapsing-remitting Multiple Sclerosis |
2.5% |
| Strongyloidiasis |
2.5% |
| Depression |
2.3% |
| Diabetes Mellitus |
2.3% |
| Diuretic Therapy |
2.3% |
| Hyperglycaemia |
2.3% |
| Insomnia |
2.3% |
|
| Rhabdomyolysis |
22.4% |
| Stillbirth |
11.2% |
| Grand Mal Convulsion |
6.5% |
| Myalgia |
6.5% |
| Urinary Incontinence |
5.6% |
| Asthenia |
4.7% |
| Neutropenia |
4.7% |
| Death |
3.7% |
| Tachycardia |
3.7% |
| Abortion Spontaneous |
2.8% |
| Arthralgia |
2.8% |
| Convulsion |
2.8% |
| Delirium |
2.8% |
| Muscular Weakness |
2.8% |
| Myopathy Toxic |
2.8% |
| Neurotoxicity |
2.8% |
| Productive Cough |
2.8% |
| Skin Atrophy |
2.8% |
| Staphylococcal Infection |
2.8% |
| Strongyloidiasis |
2.8% |
|
